FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


FJ EXPRESS SUMMARY ARTICLE
The
Full-length version of this article is also available, published online March 5, 2003 as doi:10.1096/fj.02-0807fje.
Published as doi: 10.1096/fj.02-0807fje.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/8/947
02-0807fjev1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LEE, S. Y.
Right arrow Articles by CHIUEH, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEE, S. Y.
Right arrow Articles by CHIUEH, C. C.
(The FASEB Journal. 2003;17:947-948.)
© 2003 FASEB

17ß-Estradiol activates ICI 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection1

SANG Y. LEE*, TSUGUNOBU ANDOH{dagger}, DENNIS L. MURPHY and CHUANG C. CHIUEH2

Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA;
* Department of Neuroscience and Anatomy, Penn State University College of Medicine, M.S. Hershey Medical Center, Hershey, Pennsylvania, USA; and
{dagger} Department of Applied Pharmacology, Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Toyama 930-0194, Japan

2Correspondence: NIMH, NIH 10/3D-41, Bethesda, MD 20892-1264, USA. E-mail: chiueh{at}helix.nih.gov

SPECIFIC AIMS

This new research idea on estrogen was derived from our recent discovery that preconditioning-induced neuroprotection is mediated by cGMP-dependent new protein synthesis—in particular, expression of the redox protein thioredoxin (Trx). The original aim was to investigate receptor-mediated, cGMP-dependent induction of cytoprotective proteins as the possible molecular mechanism underlying estrogen-induced neuroprotection at physiological concentrations (<10 nM).

PRINCIPAL FINDINGS

It is known that 17ß-estradiol induces NOS1 and NOS3, increases the synthesis of •NO, and activates cGMP-dependent PKG signaling. However, it is not clear whether activation of NOS1 in neurons by estrogen would lead to an increase in Trx expression or play a role in estrogen-mediated neuroprotection. After confirming that 17ß-estradiol can concomitantly induce NOS1 and neuroprotection against oxidative stress in human SH-SY5Y cells at low nanomolar concentrations (<10 nM), we make the following interesting observations.

  1. 17ß-Estradiol (<10 nM), the most potent estrogen, induced NOS1 and activated cGMP-dependent PKG and its signal transduction pathway to increase expression of the redox protein Trx for enhancing cell viability
  2. In addition to induction of NOS1 and Trx, 17ß-estradiol induced MnSOD but not BDNF or HO-2
  3. 17ß-Estradiol-induced antioxidative and cytoprotective effects were blocked by ICI 182,780, a selective inhibitor of estrogen receptor (ER), and by pharmacological agents against NOS1, guanylyl cyclase, PKG, and Trx reductase
  4. ER-enhanced cell viability against oxidative stress may be linked to Trx expression

Viability against oxidative stress may be linked to Trx expression because the cytoprotective effect of 17ß-estradiol was significantly reduced by the Trx reductase inhibitor 5, 5'-dithio-bis(2-nitrobenzoic acid) (DTNB). Consistently, Trx (1 µM) inhibited lipid peroxidation, proapoptotic caspase-3, and cell death during oxidative stress caused by serum deprivation. Pharmacological and molecular biological data indicate that cGMP-dependent expression of Trx may play a pivotal role in estrogen-induced neuroprotection. The present report is the first to link estrogen-induced neuroprotection to the observed chain of events following the activation of ICI 182,780-sensitive ER. The proposed neuroprotective pathway induced by estrogen at physiological concentrations includes induction of NOS1, activation of the cGMP-dependent protein kinase pathway, and sustained expression of Trx, a redox protein with potent antioxidative and antiapoptotic properties (Fig. 1 ).



View larger version (38K):
[in this window]
[in a new window]
 
Figure 1. Proposed cGMP-mediated neuroprotective pathway of physiological concentrations of 17ß-estradiol in the human neuroblastoma SH-SY5Y cell model. Binding of nanomolar levels of 17ß-estradiol with ER{alpha} and ERß, which are sensitive to blockade by a selective receptor antagonist ICI 182,780 (i). 17ß-estradiol induces NOS1 in brain neurons and other cells, including SH-SY5Y cells (ii). Estrogen-induced expression of NOS1 leads to the formation of nitric oxide (•NO) and activation of the cGMP and PKG-mediated signaling pathway (iii), which can induce synthesis of cytoprotective proteins such as the redox protein Trx (iv), thereby enhancing cellular defense systems (v). In addition to inhibition of lipid peroxidation (LP) and caspase-induced apoptosis, Trx induced MnSOD to suppress the generation of reactive oxygen species (ROS) in mitochondria. These results suggest that neuroprotection induced by physiological concentrations of estrogen (<10 nM) is mediated by both antioxidative and antiapoptotic actions produced by Trx and MnSOD. Consistently, the observed cytoprotective effects of 17ß-estradiol were blocked by selective inhibitors against ER (ICI 182,780), NOS1 (7-nitroindazole or 7-NI), guanylyl cyclase (LY-83583), PKG (Rp-8-pCPT-cGMPs), and Trx reductase (DTNB), respectively. Trx-overexpressing animals are less vulnerable in ischemia-induced brain injury. Trx also protects SH-SY5Y and PC-12 cells against severe oxidative stress and damage caused by 1-methyl-4-phenylpyridinium. cGMP-dependent induction of cytoprotective proteins such as Trx and MnSOD may play a pivotal role in enhancing cell viability to promote neuroprotection after treatment of human SH-SY5Y neurotrophic cells with 17ß-estradiol at nanomolar concentrations.

CONCLUSIONS

This original neuroprotection hypothesis of estrogen was based on gender differences in brain response to ischemia-reperfusion injury. 17ß-Estradiol has recently been shown to improve cognition in some postmenopausal women with senile dementia of the Alzheimer type. It was recently proposed that estrogen produces its neuroprotection through both receptor-independent and -dependent mechanisms. In ischemic animal models, estrogen may activate ER{alpha} and increase Bcl-2 for neuroprotection. Our unpublished RT-PCR results indicate that human brain-derived SH-SY5Y cells contain ER{alpha} and ERß (D. Huang, T. Andoh, and C. C. Chiueh, unpublished results). The present results reveal that low nanomolar concentrations of 17ß-estradiol activated ICI 182,780-sensitive ER in SH-SY5Y cells, leading to protection against serum deprivation-induced oxidative stress and neurotoxicity. Binding of 17ß-estradiol to ER may promote a high affinity binding of ER–DNA binding domain homodimers to estrogen response elements for regulating genes in target cells. ER{alpha} and ERß play different roles in gene regulation. ERß rather than ER{alpha} mediates transcriptional activation of NOS1 by 17ß-estradiol. There is a severe degeneration of neuronal cell bodies throughout the brain, especially in the substantia nigra of 2-year-old ERß knockout mice. It is highly likely that ERß gene, protein, and related signaling transduction pathways may be necessary not only for up-regulating NOS1 but also for neuronal survival, thereby playing an important role in the pathogenesis of neurodegenerative diseases in the brain.

It is known that nitric oxide (i.e., S-nitrosoglutathione), 8-bromo-cGMP, and Trx each protect cells and brain neurons against oxidative stress. This study is the first to link the estrogen-induced neuroprotection to a nitric oxide-mediated chain of molecular events after the induction of NOS1 by 17ß-estradiol, such as activation of the cGMP-dependent protein kinase pathway and the delayed, sustained expression of Trx. In addition to suppressing lipid peroxidation, membrane permeable Trx-(S)2 (1 µM) blocked the catalytic activity of the proapoptotic caspase-3 induced by serum deprivation in SH-SY5Y cells. Moreover, the present results revealed that estrogen-mediated cytoprotection can be prevented by the blockade of redox cycling of Trx from the inactive oxidized Trx-(S)2 to active reduced Trx-(SH)2 by a potent Trx reductase inhibitor, DTNB. Owing to its redox-active cysteinyl sites (-Trp-Cys32-Gly-Pro-Cys35-Lys-), reduced Trx-(SH)2 profoundly modulates thiol-containing transcription factors (i.e., AP-1, NF-{kappa}B) and enzymes such as caspases, NOS, Ref-1, ASK1, p53, and p21.

The present results further demonstrate that after induction of Trx, estrogen increased MnSOD expression in SH-SY5Y cells. MnSOD expression in mitochondria would augment antioxidative effects of Trx. This Trx-dependent neuroprotective mechanism of estrogen could foster research and development of selective ER modulators for neuroprotection devoid of female hormone activity and associated carcinogenesis. The present results thus infer that 17ß-estradiol-enhanced expression of Trx may be the missing link between NOS1 expression and neuronal survival after treatment with estrogen. The present results are consistent with our prior proposal that cGMP-dependent neuroprotection is mediated by Trx because it can be blocked by Trx mRNA antisense. It is concluded that the proposed ICI 182,780-sensitive ER mediate induction of NOS1, activation of the signaling pathway of •NO-cGMP-PKG, thereby leading to the cGMP-dependent induction of cytoprotective proteins such as Trx and MnSOD and enhancing cell viability with the promotion of neuroprotection.

FOOTNOTES

1 To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.02-0807fje; to cite this article, use FASEB J. (March 5, 2003) 10.1096/fj.02-0807fje




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
A. Masood, A. Nadeem, S. J. Mustafa, and J. M. O'Donnell
Reversal of Oxidative Stress-Induced Anxiety by Inhibition of Phosphodiesterase-2 in Mice
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 369 - 379.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. R. Thom, V. M. Bhopale, D. J. Mancini, and T. N. Milovanova
Actin S-Nitrosylation Inhibits Neutrophil {beta}2 Integrin Function
J. Biol. Chem., April 18, 2008; 283(16): 10822 - 10834.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
A.-M. O'Carroll, S. J Lolait, and G. M Howell
Transcriptional regulation of the rat apelin receptor gene: promoter cloning and identification of an Sp1 site necessary for promoter activity
J. Mol. Endocrinol., February 1, 2006; 36(1): 221 - 235.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
C. C. CHIUEH, T. ANDOH, and P B. CHOCK
Induction of Thioredoxin and Mitochondrial Survival Proteins Mediates Preconditioning-Induced Cardioprotection and Neuroprotection
Ann. N.Y. Acad. Sci., May 1, 2005; 1042(1): 403 - 418.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Benvenuti, P. Luciani, G. B. Vannelli, S. Gelmini, E. Franceschi, M. Serio, and A. Peri
Estrogen and Selective Estrogen Receptor Modulators Exert Neuroprotective Effects and Stimulate the Expression of Selective Alzheimer's Disease Indicator-1, a Recently Discovered Antiapoptotic Gene, in Human Neuroblast Long-Term Cell Cultures
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1775 - 1782.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
B. J. Deroo, S. C. Hewitt, S. D. Peddada, and K. S. Korach
Estradiol Regulates the Thioredoxin Antioxidant System in the Mouse Uterus
Endocrinology, December 1, 2004; 145(12): 5485 - 5492.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Xia and T. L. Krukoff
Estrogen Induces Nitric Oxide Production via Activation of Constitutive Nitric Oxide Synthases in Human Neuroblastoma Cells
Endocrinology, October 1, 2004; 145(10): 4550 - 4557.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/8/947
02-0807fjev1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LEE, S. Y.
Right arrow Articles by CHIUEH, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEE, S. Y.
Right arrow Articles by CHIUEH, C. C.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS